xRead - September 2022

Wise et al.

Page 429

Baena-Cagnani et al. 1828 2003 1b DBRCT SAR and asthma (n = 924): 1 Desloratadine 5 mg; 2 Montelukast 10 mg; 3 Placebo TASS, FEV1, β -agonist medication use Desloratadine vs placebo: reduction in mean TASS, improvement in FEV1, reduction in average β - agonist medication use. Desloratadine vs montelukast: No differences. Berger et al. 1829 2002 1b DBRCT AR and asthma (n = 326): 1 Desloratadine 5 mg; 2 Placebo. TSS, asthma symptom scores, β -agonist medication use crossover

Author Manuscript Author Manuscript Author Manuscript Author Manuscript TABLE X.A.4-1. Study

design Study groups Clinical endpoint Conclusion

Cetirizine reduced asthma and rhinitis symptoms. No difference in albuterol use. No difference in PFTs, PC 20 , and patient PEFRs. No difference in asthma management. a

Desloratadine reduced rhinitis symptoms, asthma TSS, and β -agonist medication use.

a Note small sample size and no power-analysis or sample size calculation which limits interpretation of negative findings. AR = allergic rhinitis; BHR = bronchial hyperresponsiveness; DBRCT = double blind randomized controlled trial; FEV1 = forced expiratory volume in 1 second; LOE = level of evidence; NBI = Nasal Blocking Index; PC 20 and PD 20 = provocation “concentration” or “dose” of methacholine causing a 20% decrease in FEV1 (also described as PD 20 FEV 1 ); PEFR = peak expiratory flow rate; PFT = pulmonary function test; QOL = quality of life; SAR = seasonal allergic rhinitis; SF-36 = The Short Form Health Survey; TASS = Total Asthma Symptom Severity Score; TSS = Total Symptom Score.

Rhinitis and asthma symptoms reduced with levocetirizine. Rhinasthma QOL score reduced with levocetirizine. No differences in SF-36.

BHR: increase with cetirizine; NBI: reduced with cetirizine compared to placebo at 6 hours.

Improvement in asthma symptoms with cetirizine. No differences in objective measures.

BHR (measured as methacholine PD 20 ). NBI (measured using peak expiratory

Daily rhinitis and asthma symptoms, medication use, PEFR, PC 20 , PFTs, asthma management

flow meter and calculated as [oral peak flow – nasal peak flow] divided by oral peak flow).

Daily rhinitis and asthma symptoms, QOL by Rhinasthma questionnaire and SF-36

Rhinitis and asthma symptoms, pulmonary function by spirometry

Pasquali et al. 1827 2006 1b DBRCT Persistent AR and asthma (n = 50): 1 Levocetirizine 5 mg; 2 Placebo

1 Cetirizine;

2 Placebo

Aaronson 1830 1996 1b DBRCT AR and perennial asthma (n = 28): 1 Cetirizine 20 mg daily; 2 Placebo

Grant et al. 1831 1995 1b DBRCT AR and asthma (n = 186): 1 Cetirizine 10 mg daily; 2 Placebo

SAR and asthma (n = 12):

Evidence for oral H1 antihistamines for the treatment of asthma in the context of coexistent allergic rhinitis Study Year LOE Aubier et al. 1804 2001 1b DBRCT,

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.